Video

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

18 June 2026
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

18 June 2026
Brentuximab vedotin added to CHEP (CHEPA) improves response in CD30+  peripheral T-cell lymphomas

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

18 June 2026
Blinatumomab replaces intensive chemotherapy in high-risk paediatric ALL, improving survival

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

18 June 2026
Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer

17 June 2026
Metronomic chemo + nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

17 June 2026
STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

10 June 2026
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

10 June 2026
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

10 June 2026
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

10 June 2026
Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

9 June 2026
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

9 June 2026
Back to Top